You are here

Article Text

Article menu
Download PDFPDF
Correspondence
More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia
  1. Gianfranco Ferraccioli
  1. Department of Rheumatology, Policlinico Universitario Agostino Gemelli, Universita' Cattolica del Sacro Cuore, Roma, Lazio, Italy
  1. Correspondence to Professor Gianfranco Ferraccioli, Department of Rheumatology, Policlinico Universitario Agostino Gemelli, Universita' Cattolica del Sacro Cuore, Roma 00168, Lazio, Italy; gianfranco.ferraccioli{at}unicatt.it

https://doi.org/10.1136/annrheumdis-2020-218523

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I read with great interest the paper by Della Torre et al on the effects of sarilumab in severe acute respiratory syndrome coronavirus 2 severe-critical pneumonia. They show that sarilumab treated and standard of care (SOC) treated patients present a mortality rate which is statistically not different (n 28 SARI=7% vs n 28 SOC=18%; p=NS).1 These data confirm previous data from the same group; when analysing patients treated with tocilizumab, they showed no statistically significant differences (n 33 SOC=33%, mortality vs tocilizumab (TOCI) n 32=16%, p=NS).2 These data seem to suggest that interleukin (IL)-6 is not the main target. Indeed out of more than 20 studies reported so far in the literature, only half reported clinically significant results (paper submitted). The various studies have so many bias and differences that a definite conclusion is impossible. However, since the approach with biologics has a strong rationale in controlling …

    View Full Text

    Linked Articles